Learn More
AIMS Recently, transcatheter aortic valve replacement (TAVR) has evolved as the standard treatment in patients with inoperable aortic valve stenosis. According to TAVR guidelines, body computed tomography (CT) is recommended for pre-procedural planning. Due to the advanced age of these patients, multiple radiological potentially malignant incidental(More)
OBJECTIVES The ACURATE TA(™) Aortic Bioprosthesis and Delivery System (Symetis S.A., Ecublens, Switzerland) is a new transcatheter aortic valve designed for transapical implantation. The six-month results from the completed first-in-man study are reported. METHODS The Symetis ACURATE TA(™) is composed of a porcine biological tissue valve attached to a(More)
OBJECTIVES Device-related infections remain a considerable problem of left-ventricular support. We compared the device-related-infections between the HeartMate left ventricular assist device (LVAD) and the Jarvik 2000 permanent LVAD, a device with a novel retroauricular power-supply. METHODS Between December 2000 and September 2002 we implanted the(More)
OBJECTIVE Trans-apical aortic valve implantation (TA-AVI) has evolved into a standard approach for high-risk, elderly patients using the balloon-expandable Edwards SAPIEN™ prosthesis. As an alternative device, a self-expanding sub-coronary trans-apical bioprosthesis was evaluated. METHODS The Symetis Acurate™ trans-catheter heart valve is composed of a(More)
The development of “transcatheter aortic valve implantation (TAVI)” is changing the field of cardiovascular medicine rapidly. The basic principle of TAVI is the percutaneous implantation of a bioprosthesis mounted in a metal frame. The prosthesis, which is attached to the tip of the catheter, is positioned in the native aortic valve and expanded. The first(More)
BACKGROUND This study aims at analyzing complication-induced additional costs of patients undergoing transcatheter aortic valve replacement (TAVR). METHODS In a prospective observational study, a total of 163 consecutive patients received either transfemoral (TF-, n=97) or transapical (TA-) TAVR (n=66) between February 2009 and December 2012. Clinical(More)
AIMS Little is known about how "Heart Team" treatment decisions among patients suitable for either surgical aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI) are made under routine conditions. METHODS AND RESULTS The "Heart Team" decision-making process was analysed with respect to124 patients of a non-randomised prospective(More)
Within the last few years the importance of the internal mammary artery (IMA) for coronary revascularization has increased rapidly. Although there is no doubt about the superior long-term patency of this artery in comparison to saphenous vein grafts, the discussion about early postoperative results is controversial. The aim of the present study was to(More)
BACKGROUND Little is known about preoperative predictors of resource utilization in the treatment of high-risk patients with severe symptomatic aortic valve stenosis. We report results from the prospective, medical-economic "TAVI Calculation of Costs Trial". METHODS In-hospital resource utilization was evaluated in 110 elderly patients (age ≥ 75 years)(More)
From the *Department of Diagnostic Radiology, University Hospital Freiburg, Freiburg, Germany; †Department of Cardiology, University Hospital Freiburg, Freiburg, Germany; and the ‡Department of Cardiovascular Surgery, University Hospital Freiburg, Freiburg, Germany. Manuscript received May 27, 2010, accepted June 2, 2010. A79-year-old woman with known(More)